Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR17 | Q13304 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.37 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4293284 | 0.79 | BRAF (0.44) | CYP3A4KMT2AMAPTMEN1ALDH1A1 | |
| SCHEMBL22499169 | 0.76 | ALDH1A1 (0.40) | CYP3A4KMT2AMAPTPOLBALDH1A1 | |
| SCHEMBL4293290 | 0.75 | KDR (0.44) | KMT2AMEN1 | |
| SCHEMBL2921155 | 0.74 | ALDH1A1 (0.38) | CYP3A4KMT2AMAPTPOLBALDH1A1 | |
| SCHEMBL5253685 | 0.74 | ALDH1A1 (0.38) | CYP3A4KMT2AMAPTPOLBALDH1A1 | |
| SCHEMBL4284792 | 0.73 | KDR (0.43) | KMT2AMAPTMEN1NPSR1ALDH1A1 | |
| SCHEMBL2745538 | 0.73 | KMT2A (0.36) | CYP2C19CYP3A4CYP2C9KMT2AGAA | |
| SCHEMBL22189756 | 0.69 | ALDH1A1 (0.41) | CYP3A4KMT2AMAPTPOLBALDH1A1 | |
| SCHEMBL4286199 | 0.69 | CYP2C9 (0.46) | GPR17CYP2C19CYP2C9KMT2AGAA | |
| SCHEMBL4286202 | 0.69 | CYP2C9 (0.46) | GPR17CYP2C19CYP2C9KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2162445-B1 | HETEROBICYCLIC COMPOUNDS AS KINASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2013-11-27 | — | — | EP | disclosed |
| US-8304557-B2 | Fused heterocycle derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-06 | — | — | US | disclosed |
| US-20090163488-A1 | FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163488-A1 | FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF | NOX3, NOX5, ZYX | GPR17 3128/4885CYP2C19 1345/4885CYP1A2 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.